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Abstract
Background: The practice of allergology varies widely between countries, and the costs and sales for 
the treatment of rhinitis differ depending on practices and health systems. To understand these differences 
and their implications, the rhinitis market was studied in some of the EU countries. 
Methods: We conducted a pharmaco-epidemiological database analysis to assess the medications that 
were prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA  platforms for 
prescribed medicines (MIDAS® - Meaningful Integration of Data, Analytics and Services) and for OTC 
medicines (OTC International Market Tracking - OTCims). We selected the five most important markets in 
the EU (France, Germany, Italy, Poland and Spain). 
Results: Intra-nasal decongestants were excluded from the analyses because they are not prescribed for 
allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of 
SU, the four other countries are similar. For costs, Poland is lower than the three others. However, 
medication use differs largely. For 2018, in SU, intra-nasal corticosteroid is the first treatment in Poland 
(70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%) whereas the Italian market is dominated by 
systemic anti-histamines (41.4%) followed by intra-nasal corticosteroids (30.1%). Results of other years 
were similar.
Discussion: There are major differences between countries in terms of rhino-conjunctivitis medication 
usage.
Key words: allergic rhinitis, medications, MIDAS, costs, units
Abbreviations
AR: Allergic rhinitis
ARIA: Allergic Rhinitis and its Impact on Asthma
ATC: Anatomical Therapeutic Chemical
DDD: Defined daily dose
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LEU: Local Currency Euro
MASK: Mobile Airways Sentinel networK
MIDAS: Meaningful Integration of Data, Analytics and Services
MNF: Manufacturer Price Level
OTC: Over-the-counter
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Introduction
Allergic rhinitis (AR) is one of the most common chronic conditions . Available treatments include allergen 
avoidance, pharmacotherapy with H1-antihistamines or intranasal corticosteroids (INCS), and allergen-
specific immunotherapy (AIT) (1). Many patients are dissatisfied with their treatment for many reasons. 
Management does not consider the patient’s needs, no cure is available, adherence to long-term therapy is 
poor and/or the patients do not fully understand their condition. Real-world data obtained via mobile 
technology have suggested that there are differences in medication use between countries (2, 3)
MASK-air (4-6) is a Good Practice of DG Santé concerning the digital transformation of health (7, 8). The 
practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis 
differ depending on practices and health systems. To understand these differences and their implications, it 
is important to have an overall view of the rhinitis market in some of the EU countries.
The goal of the paper was to assess practices in different EU countries in order to better implement the 
Good Practice of DG Santé (MASK-air). The secondary goal was to understand some of the differences to 
propose mitigation strategies. This study will serve as a baseline status for possible future measures to be 
taken at the country level.
Methods
Study design
This ARIA study evaluated the market for allergic rhinitis (AR) treatment (prescribed and over-the-counter 
- OTC medications) in five EU countries in the years 2016-18. We conducted a pharmaco-epidemiological 
database analysis to assess the medications that were prescribed for allergic rhinitis during the years 2016, 
2017 and 2018. We used the IQVIA (collaboration between Quintiles and IMS Health under the name 
“IQVIA”) platforms for prescribed medicines (MIDAS® - Meaningful Integration of Data, Analytics and 
Services) (9-11) and for OTC medicines (OTC International Market Tracking - OTCims) (12). PharMetrics 
Plus database (IQVIA), a large health claims database captures demographics, physician visits, 
hospitalizations and  prescription drugs.  All medical diagnoses are captured through International 
Classification of Diseases, Ninth and Tenth Editions (ICD-9 and -10). This database  also  captures  all  
outpatient  prescription drugs. This includes drug identification, dose prescribed, and treatment duration. 
We used manufacturing costs and not the costs for the health care system as in some countries there are 
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Medications 
Definitions used
We used SU (Standard Units) and LEU/MNF (Local Currency Euro/ Manufacturer Price Level) to compare 
data between countries. 
An SU is a unit defined by IQVIA to represent the smallest daily unit of consumption, e.g. one tablet, one 
vial/ampoule or 5 ml of liquid. As an example, a pack of 100 tablets with a dosage recommendation of 2 
tablets a day will lead to: Unit = 1, Counting Units = 100 and SU = 50. 
LEU/MNF per year represents the total sales in Local Currency Euro at Ex-Manufacturer Price Level per 
Calendar Year.
We chose Manufacturing Cost of the drugs and it was not possible to mention health care system costs 
because there are rebates that are not publicly available.
Selection of medications  
We selected medications registered for AR, as well as nasal or ocular decongestants since these 
medications may also be administered for AR.
The World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC)  classifies drugs by their 
active ingredients (13) and their defined daily dose (DDD), a fixed attribute that allows the conduct of 
national or international drug use studies (14). This ATC system is based on the earlier Anatomical 
Classification System, which was intended as a tool for the pharmaceutical industry to classify 
pharmaceutical products (as opposed to their active ingredients) (15). This system was initiated in 1971 by 
the European Pharmaceutical Market Research Association (EphMRA) (16, 17). In the present study, we 
used the EphMRA system and we gave the ATC correspondence.
For prescribed medications, the study was performed by IQVIA Ltd., London, England using de-identified 
prescription data from MIDAS® for 2016, 2017 and 2018 (in € for sales as well as numbers of treatments). 
MIDAS® provides connectivity and international standardization of national-level pharmaceutical audits to 
allow cross-country analysis of company and product performance, as well as additional insights and 
attributes not available at a local level. MIDAS® captures and harmonizes the data from 92 countries 
worldwide mainly for registered medicines (prescription and non-prescription) in pharmacy and hospital 
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volumes, trends and market share by product and therapy class, through retail and non-retail channels. 
MIDAS® tracks the direct sales (i.e., sales invoices) of pharmaceuticals from the manufacturer to 
pharmacies or hospitals. MIDAS® also tracks indirect sales (sales going through a middleman i.e., the 
wholesaler) to pharmacies and hospitals. MIDAS® tracks inflow or what these different channels are 
purchasing (i.e., the sales made into those outlets). It represents the full European market through 
representative panel projections for both retail and hospital channels. 
The following subgroups include symptomatic AR drugs and ophthalmic drugs (since rhinitis is often 
associated with conjunctivitis). Montelukast was not used as it is both an anti-asthma and rhinitis treatment 
and is only indicated in patients with both rhinitis and asthma. The following medications were considered 
(Table 1A).
For OTC medications, the QuintilesIMS OTCims (OTC International Market Tracking) database was used. 
OTCims is a Customised Global Information Offering providing granular data for the effective tracking of 
company and competitor performance in the Consumer Health marketplace. It uses IQVIA Consumer 
Health Classification based on Market Positioning. Data are available across four main market segments: 
OTC, Personal Care, Patient Care and Nutrition. Data are included for 36 countries from Europe, Asia 
Pacific, North and Latin America. Clients are supported in both own as well as competitor product/pack 
performance tracking against key performance indicators. 
The MIDAS® database does not identify the disease for which the medication has been used.  This is the 
case for systemic antihistamines (R06A0) which include treatments for the nose, skin and other organs. 
They cannot be distinguished. INCS (R01A1) can also be administered for AR, non-allergic rhinitis and 
rhinosinusitis. 
The list of OTC medications is given in Table 1B. The four OTC therapy classes include “oral H1-
antihistamines” and “INCS”. The list is too far from ATC to propose any correspondence.
Allergen specific immunotherapy
The only country where AIT is mostly delivered in pharmacies is Germany. We only provided data for AIT 
in Germany
Selection of countries
The market for prescribed medications (in costs for patients) for 2018 in all EU countries was ranked in 









This article is protected by copyright. All rights reserved
in the country selection because a single database cannot be used in all countries. AIT was not considered 
in the country selection since large variations exist between countries in terms of supply (pharmacies, 
hospitals, Named-Patient Products …).
The first six countries with the highest sales for AR medications and nasal decongestants were France, 
Germany, Italy, Spain, Poland and the UK. There was a big gap between UK N°6 and Sweden N°7. Thus, 
we considered only the first six countries. In the UK, a significant proportion of sales took place in 
supermarkets and these were not considered by IQVIA. Thus, the country had to be excluded.
The “Sell-Out” (Medication dispensed in pharmacies) data and, if not available, the “Sell-In” (Medication 
delivered in pharmacies) data were obtained from IQVIA. For the countries selected, the databases were 
from different origins and the data type differed taking into account the country specificities on drug 
dispensing (Table 2).
Collection of information
There are different methods of collecting the information and we needed to make assumptions. 
It is possible to compare “Sell-in” (from wholesaler to retail pharmacy, effects like stocking are included) 
and “Sell-out” (from retail pharmacy to patient) data bearing in mind some biases.  . Therefore, for one 
quarter, the “Sell-in” data might be higher when compared to “Sell-out” due to stock, but these effects are 
minimized for yearly data. In the countries tested, “hospital” means hospital consumption from hospital to 
patient.
For the OTCims Panel, all panels are “Sell-out”. 
Analyses
We conducted a descriptive analysis to evaluate the medications used in different countries. To derive 
figures for anti-rhinitis consumption per person over the three years, we linked consumption by SU to 
population estimates.
Stratification:  The analyses were performed for prescription data and OTC data separately. In some 
countries, the same products could be prescribed and also available OTC. Thus, in order to prevent multiple 
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Data periods: The analyses covered the periods 2016, 2017 and 2018. Results were processed on a yearly 
basis.
Analyses were performed once at the same time. 
Projection: The results were projected yearly per country.
Results
Intra-nasal decongestants (R1A7 and 01B2)
Intra-nasal decongestant sales (R1A7 and 01B2) are extremely variable, with low sales in France (from 
612,073 to 751,739 kSU per year, 12.6% to 14.8% of total sales) and high sales in Germany (from 
6,586,460 to 6,890,822 kSU per year, 71.6 to 79.6%) (Table 3). We checked the monthly variation of 
R1A7 in Germany in 2018 and found that they were purchased less often during the pollen season than 
outside (Figure 1 online). In Germany, although the majority of products were available in pharmacies, 
they were non-prescribed. We therefore excluded R1A7 and 01B2 from further analyses as they are 
unlikely to represent patients with allergic rhinitis.
Overall results without intranasal decongestants (R1A7 and 01B2)
The results are presented in Tables 2 online and 4 and in Figure 1. For both SU and costs, France is leading 
the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the 
three others. However, medication use differs largely. For 2018, in SU, INCS is the first treatment in 
Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%) whereas the Italian market is 
dominated by systemic anti-histamines (41.4%) followed by INCS (30.1%). Results of other years are 
similar. MPAze-Flu (DYMISTA) represented from less than 1% in Spain to 1.5% in Poland and Germany 
and around 2.6 % in France of SU in 2018. 
In costs for 2018, INCS represent 20.7% of the market (Poland), around 26-28% (Germany, Italy, Spain) 
and up to 38.6% (France). Systemic antihistamines represent from 45.8% (Italy) to 49.3% (France), 57 to 
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Rhino-conjunctivitis medication consumption per person in Europe
There are very large differences in medication consumption (SU) per person in Europe depending on the 
country (Table 5). In France, there are 4.3 times more INCS sold per inhabitant than in Germany. On the 
other hand, in Germany, there are 9.25 times more nasal decongestants sold per inhabitant than in France. 
Although the proportion of reimbursement/out of pocket differs between countries, and even, in the same 
country, for different classes of drugs, reimbursement and OTC availability of medications differ in EU 
countries (Table 3 online). 
Allergen immunotherapy
In Germany, AIT represents an between 33.2 to 37.3% of LEU/MNF (Table 3).
Discussion
The present paper shows that there is a great heterogeneity in AR medications across Europe. Some 
explanations may be proposed including reimbursement strategies.
Limitations
Although the IQVIA platform appears to be a good source of data for estimating drug consumption in 
different countries, there are several limitations.
First, we can only use the classification of medications proposed by IQVIA and some classes are assessing 
medications for multiple diseases such as “Systemic anti-histamines”. It is likely that their use differs 
between countries and that the results reported in this paper may not be totally comparable.  
Second, In the IQVIA database, medications are not classified by disease and there are overlaps between 
skin and respiratory diseases as well as for respiratory diseases, there are different indications such as 
allergic and non-allergic rhinitis or rhinosinusitis.
Third, we had to make assumptions that were discussed in the methods. It does not seem that these 
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Third, another limitation is non-adherence to prescribed drugs in patients that cannot be estimated. Thus, 
the results of the study do not consider lack of adherence to medication that was reported to be quite high 
(18).
Fourth, exclusion of nasal decongestants was proposed because they are not indicated in AR and they are 
largely used for common cold and cough in some countries. The BSCAI guidelines (the only European 
guidelines) (19) and ARIA (global guidelines) (20) that are used in most European countries do not 
recommend the regular use of intra-nasal decongestants. In ARIA, the last recommendation was in 2010 
since there has not been any other important paper on the subject since then. “In adults with AR and severe 
nasal obstruction, we suggest a very short course (not longer than 5 days and preferably shorter) of 
intranasal decongestant while co-administering other drugs (conditional recommendation, very low-quality 
evidence). We suggest that clinicians do not administer and parents do not use intranasal decongestants in 
preschool children (conditional recommendation j very low-quality evidence). “ A report by Statistica 
(https://www.statista.com/statistics/417727/cough-and-cold-self-medication-market-sales-in-europe/) 
showed the same ranking order for cold and cough drugs as the IQVIA data for nasal decongestants with 
Germany ranking first (1,557 million € for 2017), followed by Italy (718), Poland (609), Spain (552) and 
France (490). In Germany, in 2018, the months with the highest pollen counts were those with the lowest 
use of nasal decongestants. 
Interpretation
Although many papers dealt with AR costs, we were not able to find any that analyzed the units sold. 
Moreover, costs are difficult to compare between papers as OTC and prescribed drugs vary between 
countries and AR direct costs reduced considerably when medications became OTC. In the present paper, 
we found large differences between EU countries, and particularly between France (low nasal 
decongestants, high INCS consumption) and Germany (the opposite). 
In a Swedish study, it was found that 71.6% of patients with AR were using OAH, 44% INCS and 41% 
nasal decongestants (21).  
In France, most medications are reimbursed if prescribed. A long wait to consult French medical specialists 
encourages quick purchases of OTC drugs, during pollen seasons for example. French pharmacists are 
often well trained for offering OTC drugs: easy-to-use, inexpensive oral OAH, nasal sprays and eye drops. 
ENT physicians and allergists traditionally prescribe these molecules and train general practitioners to do 
so too. These molecules were prescribed very early by paediatricians, also in children of atopic families 
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In Germany, the situation is more complex than in other countries. The general reimbursement strategy is 
outlined in Table 3. 8.7% of the population are privately insured, this is only possible for people who are 
self-employed or for employees who earn an above-average salary.  For privately-insured patients, all 
allergic rhinitis medications are usually reimbursed but it depends very much on the individual contracts.  
Some privately-insured patients for instance have a contract where they are only reimbursed for medication 
and other healthcare costs above a chosen limit, e.g. 1,000€ per year.  This is a contract which young 
people very often choose, the monthly costs being lower and with the speculation of not having to use this 
fixed rate in the year.  These patients often tend not to buy medications recommended by the physician. 
The rest of the population is under the statutory health insurance (Gesetzliche Krankenversicherung) but 
can choose between different companies offering policies. Also, the official healthcare insurance 
companies have different reimbursement strategies and details vary.  The general reimbursement strategy is 
outlined in Table 3 but another variable comes into play.  Physicians treating patients under the statutory 
health insurance scheme in Germany have a fixed budget for medication costs and can be made liable if 
they do not adhere to the very strict economic prescription pathways.  Although OAH can be reimbursed 
for severe allergic rhinitis, even if over-the-counter products are available, physicians often choose not to 
prescribe these medications on a panel prescription which allows reimbursement but to give a private 
prescription to the patient which means that he/she has to cover the full costs.  Last but not least, another 
limiting factor in Germany is the fact that all patients above 12 years of age also have to pay a cost share 
fee for every drug at the pharmacy which is 10% of the price of the product, with a minimum of 5 € and 
maximum of 10 €. 
In Italy, most medications for rhinoconjunctivitis are provided through medical prescription. OAH are 
reimbursed by the NHS - National Healthcare System, whereas INCS (including INCS+INAH ) are not, 
except in one region, Tuscany.
In Poland, the situation is similar to France.  The medications for Allergic Rhinoconjuctivitis are 
reimbursed if prescribed by the physician.  Everyone is covered by the National Health Fund (NHF), but 
the private sector is also very active.  Patients can visit specialists working under (NHF) for free but must 
wait a few months to consult or can choose to visit a private doctor and pay out-of-pocket for the service 
without having to wait.  Physicians in private and public sectors can prescribe reimbursed 
medications.  Many medications which are reimbursed if prescribed also have an OTC version, including 
INCS and OAH.  Similar to France, these molecules were prescribed very early by paediatricians, also in 
children of atopic families who present nasal symptoms. The children are used to these methods from the 









This article is protected by copyright. All rights reserved
In Spain, most medications for rhinoconjunctivitis are provided through medical prescription. Nevertheless, 
there are a few formulations which may be acquired as OTC, including some OAH, such as cetirizine, and 
INCS, such as fluticasone propionate. A recent study has calculated the direct and indirect costs of AR in 
patients attending specialized clinics in Spain (22). Data showed that the mean drug treatment per year was 
significantly higher in persistent AR (77.88 ±134.22€) compared to intermittent AR (45.62 ±78.93€). On 
the other hand, no significant differences were found when comparing mild, moderate and severe AR 
(41.77±86.02€, 70.36±127.07€ and 72.16±114.60€, respectively). Direct costs accounted for 24% of total 
costs, and drug therapy was only 10-13% of the direct costs. 
Cultural and reimbursement differences between countries may explain trends in treatment.
Many studies reported that OAH are more often used than INCS  (23-25)  and this accords with the results 
of the present study. However, this is the first multi-national study comparing medication delivery. 
The large differences between countries in INCS use are surprising since the guidelines of ARIA (26), the 
British Society of Allergy and Clinical Immunology (19) or the US Practice parameters (27) recommend 
INCS as the first line treatment for moderate to severe AR and it is likely that AR severity is similar 
between countries. However, the reimbursement strategies of some countries may impair the 
implementation of guidelines. Moreover, although most AR patients consulting a physician have moderate 
to severe rhinitis, the low level of ICNS prescribed is surprising. These data may, at least partly explain the 
poor satisfaction of AR patients.
There are also very large differences between countries in intra-nasal decongestants. Although the 
indications cannot be assessed using the IQVIA database, it is likely that many patients in Germany use 
intra-nasal decongestants for AR. This does not accord with guidelines. In ARIA, “In adults with AR and 
severe nasal obstruction, we suggest a very short course (not longer than 5 days and preferably shorter) of 
intranasal decongestant while co-administering other drugs (conditional recommendation, very low-quality 
evidence)” (20).  In the BSCAI…..
Conclusions
With the limitations discussed, this study is of great interest for assessing the heterogeneity of 
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Table 1A: Codes of prescribed medications 
Description EphMRA 
code
ATC code Application form
Nasal corticosteroids without anti-infectives R01A1 R01AD Nasal spray, drops, 
ointment
Nasal anti-allergic agent R01A6 R01AC Nasal spray, drops, 
ointment
Nasal decongestant* R01A7 R01AA + R01AB Nasal spray, drops, 
ointment
Other topical nasal preparation R01A9 R01AX Nasal spray, drops, 
ointment
Systemic rhinologic preparations (including 
oral decongestants)
R01B0 R01BA Systemic
Systemic anti-histamines R06A0 R06AA + R06AB 
+ R06AD + 
R06AE + R06AX
Systemic
Ophthalmologic anti-allergic anti-histamines S01G1 Eye drop
Ophthalmologic anti-allergic mast cell 
stabilizers
S01G2 Eye drop
Other ophthalmologic anti-allergic agents S01G3
S01GX
Eye drop
Ophthalmologic decongestants with 
sympathomimetics*
S01G5 S01GA Eye drop
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Table 1B: Codes of OTC medications
Description OTC class
Nasal Decongestants  01B2 
Respiratory & General Antiallergics  01E1 
Eye Antiallergics  07A2 
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Table 2: Origin of the databases
Countries/Panels: Country Channel Data Type
 OTCIMS France Pharmacy Sell-out
 Para-pharmacy Sell-out
Germany Pharmacy Sell-out






 Supermarkets & Hypermarkets-Corner Sell-out




MIDAS France Hospital Sell-in 
Retail Sell-in 
Germany Retail/Mail Order Sell-out
Hospital Sell-in 
Italy Hospital Sell-in 
Retail Sell-in 
Poland Hospital Sell-in 
Retail Sell-in 
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Table 3: Overall units and costs obtained by MIDAS and OTCims
Annual SU (thousands) Annual LEU/MNF (million €)
















R1A7+01B2 751,739 697,063 612,073 29,107 25,742 23,134
















R1A7+01B2 6,586,460 6,763,831 6,964,445 147,137 155,700 162,511
R1A7 prescribed 4 2 0 14 6 0
Total 8,459,887 8,577,650 8,879,580 295,744 292,462 317,369
















R1A7+01B2 908,777 897,072 945,276 52,739 55,042 57,843
















R1A7+01B2 1,039,763 1,037,053 1,029,205 44,063 47,571 47,989
















R1A7+01B2 675,098 645,544 631,286 31,317 31,703 32,392
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Table 4: Standard units (SU) and costs of medications (LEU/MNF, absolute for fiscal year) in five European 






















France 5 097 280 885 4 929 568 274 4 874 702 206 326 609 288 315 187 283 313 398 985 
HOSPITAL 24 443 211 22 347 969 24 131 960 3 994 101 3 930 879 4 164 317 
R1A1 4 430 987 3 142 635 3 408 948 323 730 307 361 336 467 
R1A7 4 165 245 3 735 215 3 600 270 61 833 52 174 48 840 
R6A0 12 383 393 12 163 848 12 668 770 3 124 229 3 209 892 3 284 036 
* DYMISTA 0 720 144 840 0 74 13 948 
S1G1 14 980 13 119 20 349 1 198 1 095 1 636 
S1G2 3 376 938 3 251 404 4 251 647 126 016 124 745 153 377 
S1G3 63 456 35 431 170 362 2 455 1 587 7 990 
RETAIL 4 690 535 231 4 530 115 204 4 493 777 976 303 069 376 292 933 322 290 997 700 
R1A1 2 281 980 628 2 205 997 152 2 182 679 986 119 602 835 114 537 298 111 803 786 
R1A7 382 849 348 334 644 594 289 028 123 12 324 480 10 578 877 9 086 817 
R6A0 1 259 075 253 1 250 282 248 1 284 035 579 140 023 134 137 490 816 139 313 337 
* DYMISTA 796 680 34 165 320 114 622 080 113 530 3 444 710 11 462 208 
S1G1 50 009 780 47 470 270 48 741 660 4 633 682 4 569 464 4 788 785 
S1G2 592 278 142 570 187 400 570 438 348 20 262 676 19 507 566 19 794 182 
S1G3 124 342 080 121 533 540 118 854 280 6 222 569 6 249 301 6 210 793 
OFF-TAKE 360 521 721 352 837 569 333 455 785 19 074 984 17 810 498 17 700 707 
01B2 343 489 664 332 041 918 297 306 639 16 300 087 14 656 459 13 563 859 
O1E1 5 346 125 7 039 683 23 249 372 821 915 938 080 1 998 837 
07A2 400 0 0 13 0 0 
07A5 11 685 532 13 755 968 12 899 774 1 952 969 2 215 959 2 138 011 
PARA PHARM 21 780 722 24 267 532 23 336 485 470 827 512 584 536 261 
01B2 21 236 429 23 640 960 22 138 035 421 973 454 114 434 148 
O1E1 341 703 422 512 978 770 44 419 52 036 96 827 
07A2 400 0 200 8 0 4 




8 474 999 252 
 
8 595 106 633 
 
8 898 547 120 
 
691 220 202 
 
686 781 024 
 
707 408 598 
HOSPITAL 249 496 527 255 184 305 250 282 157 8 711 628 7 863 795 8 272 906 
R1A1 5 474 147 5 439 325 5 575 688 324 277 282 455 299 298 
R1A7 228 397 070 234 976 448 229 199 632 2 923 767 2 942 361 2 909 478 
R6A0 13 346 015 12 761 105 13 384 968 2 066 290 1 923 863 2 484 365 
V1A0 17 442 12 954 13 269 3 335 043 2 668 134 2 524 879 
* DYMISTA 64 240 44 400 72 120 10 675 7 400 12 154 
S1G1 291 274 303 232 410 628 10 349 11 407 11 025 
S1G2 1 387 085 1 278 129 1 156 591 16 949 13 627 14 754 
S1G3 583 494 413 112 541 381 34 953 21 948 29 107 
PHMSCOPE 7 867 016 585 7 966 630 528 8 257 235 986 674 286 284 669 888 195 689 539 848 
R1A1 775 921 033 755 819 069 829 008 199 37 308 422 37 331 516 42 471 934 
R1A7 6 231 082 998 6 396 953 648 6 486 356 795 139 382 223 148 708 228 155 314 296 
R6A0 564 852 155 543 717 940 608 321 693 92 324 525 80 342 707 88 917 806 
V1A0 15 095 779 17 444 001 18 953 549 392 140 744 391 651 448 387 486 192 
* DYMISTA 36 562 768 34 240 092 36 755 760 6 093 972 5 706 703 6 165 471 
S1G1 39 119 160 33 719 080 44 437 320 2 479 823 2 128 481 2 849 695 
S1G2 106 793 840 94 276 360 104 978 800 2 957 406 2 544 410 2 862 850 
S1G3 134 151 620 124 700 430 165 179 630 7 693 141 7 181 405 9 637 075 
PHARMACY 193 137 402 210 177 201 216 417 121 5 093 515 5 681 215 5 846 784 
01B2 83 858 450 98 444 811 103 622 407 2 281 585 3 043 918 3 246 814 
07A5 100 576 690 104 101 960 105 335 380 2 088 516 2 002 415 2 000 027 
O1E1 5 926 522 4 475 960 4 168 654 578 025 481 892 452 820 
07A2 2 775 740 3 154 470 3 290 680 145 389 152 990 147 123 
DISCOUNTER 8 832 814 8 353 946 8 590 854 257 229 197 507 193 400 
01B2 8 832 814 8 353 946 8 590 854 257 229 197 507 193 400 
DRUGSTORE 113 170 473 114 023 434 124 054 013 1 999 975 2 237 524 2 572 119 
01B2 86 313 303 89 465 439 100 583 488 1 727 111 1 780 528 1 795 086 
O1E1 26 857 170 19 024 460 15 197 810 272 864 184 562 174 842 
07A2 0 4 272 160 4 959 840 0 71 889 80 231 
07A5 0 1 261 375 3 312 875 0 200 545 521 960 
S/MARKET 38 898 835 36 600 671 37 537 948 778 642 823 753 893 062 
01B2 30 506 765 30 122 121 32 530 143 733 210 724 048 766 362 
O1E1 8 392 070 4 216 660 3 629 200 45 432 51 778 51 792 
07A2 0 2 176 640 1 022 880 0 34 308 18 346 
07A5 E 0 85 250 355 725 0 13 619 56 562 
SMALL SMKT 4 446 616 4 136 548 4 429 041 92 929 89 035 90 479 
01B2 3 781 336 3 682 438 3 562 601 89 961 85 649 82 075 
O1E1 665 280 372 290 680 470 2 968 1 762 3 051 
07A2 0 81 120 172 320 0 1 512 3 166 




2 493 701 426 
 
2 460 288 900 
 
2 508 148 909 
 
221 605 769 
 
224 095 406 
 
230 723 070 
HOSPITAL 19 268 623 20 624 634 22 896 801 7 307 742 8 225 054 7 737 864 
R1A1 2 637 698 3 097 120 6 309 450 215 073 247 465 522 799 
R1A7 6 402 915 6 575 175 6 376 050 152 228 158 388 162 177 
R6A0 6 641 693 7 132 653 6 905 066 2 345 114 2 494 632 2 189 101 
V1A0 2 307 100 2 676 768 2 454 872 4 557 923 5 291 088 4 839 904 
* DYMISTA 12 628 18 840 90 240 1 854 2 762 13 228 
S1G1 O 1 120 848 1 033 981 791 298 31 163 27 931 20 146 
S1G2 8 931 18 846 3 785 448 750 179 
S1G3 149 438 90 091 56 280 5 793 4 800 3 558 
RETAIL 1 883 436 191 1 844 094 607 1 881 117 488 176 870 734 177 557 354 184 265 292 
R1A1 496 427 232 485 212 020 499 795 900 43 107 606 42 304 966 44 205 554 
R1A7 683 174 377 678 502 447 689 459 915 40 119 423 42 168 247 44 414 520 
R6A0 372 064 000 370 177 978 377 874 748 73 414 490 72 901 327 74 732 272 
V1A0 162 692 225 659 238 380 320 549 445 196 470 630 
* DYMISTA 30 759 112 31 069 200 36 225 840 6 041 621 6 102 510 7 115 358 
S1G1 230 409 525 214 051 423 215 322 465 10 608 676 10 101 835 10 384 357 
S1G2 35 852 210 31 149 190 31 040 290 2 588 674 2 362 103 2 352 370 
S1G3 65 346 155 64 775 890 67 385 790 6 711 316 7 273 680 7 705 589 
OFF-TAKE 420 390 759 426 548 277 441 534 997 29 617 267 30 277 427 30 776 362 
01B2 183 808 168 183 945 839 177 617 076 8 938 640 9 011 910 8 847 760 
O1E1 18 147 917 15 335 022 13 921 881 1 525 029 1 454 974 1 373 791 
07A2 23 223 460 24 866 070 25 146 300 1 345 096 1 761 222 2 005 317 
07A5 195 211 214 202 401 346 224 849 740 17 808 502 18 049 321 18 549 494 
PARA PHARM 41 399 851 42 567 200 42 588 137 2 863 821 2 865 082 2 796 401 
01B2 15 199 665 15 112 203 13 707 888 754 197 760 555 722 685 
O1E1 3 130 451 2 712 157 2 786 754 300 695 289 792 304 747 
07A2 811 270 1 139 910 856 970 50 091 72 531 72 711 
07A5 22 258 465 23 602 930 25 236 525 1 758 838 1 742 204 1 696 258 
MASS MARKET 113 035 642 110 123 888 104 234 591 4 326 080 4 470 655 4 382 715 
01B2 62 842 213 61 141 481 57 418 452 2 703 120 2 737 765 2 643 213 
O1E1 1 971 259 2 292 072 2 124 944 231 160 347 777 372 003 
07A2 6 867 550 6 237 605 5 858 435 244 540 227 324 215 782 
07A5 41 354 620 40 452 730 38 832 760 1 147 260 1 157 789 1 151 717 
MASS MKT-NC 16 170 360 16 330 294 15 776 895 620 125 699 834 764 436 
01B2 2 236 235 1 796 525 1 461 621 72 318 67 713 52 786 
O1E1 26 030 37 499 36 434 3 186 5 115 5 743 
07A2 62 585 66 140 67 690 2 572 2 929 2 599 




2 765 988 564 
 
2 842 199 367 
 
2 835 908 301 
 
155 134 749 
 
160 226 726 
 
164 378 170 
HOSPITAL 15 137 626 16 445 222 16 028 988 1 596 145 1 627 760 1 654 806 
R1A1 2 298 952 2 749 104 2 513 696 37 254 38 483 38 328 
R1A7 7 500 858 8 190 886 7 891 661 132 630 154 203 158 718 
R6A0 4 753 783 4 890 510 5 023 220 672 903 699 454 790 018 
V1A0 18 573 17 682 17 331 745 406 726 527 658 504 
* DYMISTA 360 1 080 4 680 59 176 663 
S1G1 376 200 407 800 388 700 4 560 5 658 5 468 
S1G2 160 400 154 620 162 200 1 578 1 622 1 783 
S1G3 28 860 34 620 32 180 1 814 1 813 1 987 
RETAIL 2 366 366 557 2 417 153 496 2 431 208 428 146 144 714 150 426 738 153 779 672 
R1A1 653 132 400 703 686 012 713 149 704 22 924 341 20 705 341 20 673 273 
R1A7 1 004 863 014 1 011 149 604 992 832 758 42 197 935 45 819 743 46 349 359 
R6A0 486 694 708 493 734 398 503 733 894 64 423 901 66 049 824 67 696 276 
V1A0 468 615 573 662 665 272 11 912 466 13 306 862 13 759 838 
* DYMISTA 6 561 360 8 876 280 21 715 680 972 582 1 273 403 2 772 401 
S1G1 32 080 900 28 343 000 26 681 800 565 844 519 091 490 397 
S1G2 142 996 760 131 793 440 139 948 300 1 440 042 1 259 054 1 311 795 
S1G3 46 130 160 47 873 380 54 196 700 2 680 185 2 766 823 3 498 734 
OFFTAKE 384 484 381 408 600 649 388 670 885 7 393 890 8 172 228 8 943 692 
01B2 27 399 224 27 711 821 27 479 770 1 732 406 1 596 898 1 479 956 
O1E1 70 555 480 59 164 147 59 134 467 2 684 702 2 764 934 3 395 491 
07A2 19 943 700 40 539 400 52 760 100 562 182 1 057 186 1 368 100 
07A5 266 585 977 281 185 281 249 296 548 2 414 600 2 753 210 2 700 145 
SPAIN 2 335 455 930 2 342 195 399 2 378 256 266 190 665 883 193 609 689 202 734 323 
HOSPITAL 9 112 183 11 052 976 10 225 055 1 513 651 1 645 761 1 560 387 
R1A1 2 172 526 3 357 987 2 535 450 50 334 86 924 75 791 
R1A7 2 005 927 2 283 341 2 158 777 88 131 93 613 92 522 
R6A0 4 027 829 4 395 427 4 440 996 1 309 209 1 392 995 1 316 609 
* DYMISTA 0 0 0 0 0 0 
S1G1 119 460 150 960 183 220 6 728 8 488 10 080 
S1G2 9 300 5 300 11 700 378 208 459 
S1G3 777 141 859 961 894 912 58 871 63 533 64 926 
SELL OUT 2 194 730 398 2 195 372 883 2 242 126 707 180 353 377 182 800 026 191 487 364 
R1A1 855 946 916 889 440 180 919 688 976 42 155 216 45 579 352 47 849 302 
R1A7 627 535 576 601 079 486 590 371 990 28 513 887 29 012 900 29 795 483 
R6A0 457 352 438 465 876 773 487 974 761 91 904 533 91 040 256 96 059 459 
V1A0 465 028 479 164 686 600 1 074 098 1 110 096 1 584 551 
* DYMISTA 9 252 292 11 344 080 12 349 804 1 233 993 1 596 132 1 852 831 
S1G1 111 263 360 102 285 020 107 474 200 5 855 324 5 514 404 5 680 404 
S1G2 33 539 100 29 905 100 29 050 300 772 194 681 761 669 877 
S1G3 108 627 980 106 307 160 106 879 880 10 078 125 9 861 257 9 848 288 
OFF-TAKE 129 508 699 131 988 535 122 727 936 8 702 319 8 969 019 9 517 896 
01B2 46 051 527 42 168 335 38 740 393 2 714 808 2 595 648 2 513 212 
O1E1 4 814 504 4 447 039 5 056 991 1 025 215 760 457 834 638 
07A2 184 714 434 790 2 210 500 57 610 131 428 218 062 
07A5 78 457 954 84 938 371 76 720 052 4 904 686 5 481 486 5 951 984 
PARAPHARM 2 104 650 3 781 005 3 176 568 96 536 194 883 168 676 
01B2 4 050 13 875 14 850 256 817 1 038 
O1E1 1 640 4 660 11 710 308 1 505 3 941 
07A5 2 098 960 3 762 470 3 150 008 95 972 192 561 163 697 
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Table 5: Rhino-conjunctivitis medication consumption in Europe per inhabitant (results in SU per year, 
2018)
Population 2015 (in 
thousands)





France 66,352 64.2 9.2 33
Germany 81,175 24.5 85.1 7.6
Italy 60,795 25.7 15.6 8.3
Poland 38,005 47.5 27.0 18.8
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Figure 1: Comparison between countries for 2018 of the number of standard units sold (SU) and costs (LEU/MNF)
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